Picture loading failed.

Anti-IL31RA therapeutic antibody (Pre-made Nemolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-372-1mg 1mg 3090
GMP-Bios-ab-372-10mg 10mg 21890
GMP-Bios-ab-372-100mg 100mg 148000
GMP-Bios-ab-372-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL31RA therapeutic antibody (Pre-made Nemolizumab biosimilar,Whole mAb)
INN Name Nemolizumab
TargetIL31RA
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesChugai Pharmaceutical;Galderma;Maruho
Conditions Approvedna
Conditions ActiveAtopic dermatitis;Prurigo nodularis;Pruritus
Conditions Discontinuedna
Development Techna